Apolipoprotein E genotype and mortality: Findings from the Cache County Study

Journal of the American Geriatrics Society

Volumn 53, Issue 6, 2005, Pages 935-942

  Hayden, Kathleen M ^a   Zandi, Peter P ^c   Lyketsos, Constantine G ^c,d   Tschanz, JoAnn T ^e   Norton, Maria C ^e   Khachaturian, Ara S ^f   Pieper, Carl F ^a,b   Welsh Bohmer, Kathleen A ^a,b   Breitner, John C S ^g,h  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UTAH STATE UNIVERSITY   (United States)

^f Khachaturian and Associates Inc   (United States)

^g VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Apolipoprotein E; Cardiovascular disease; Mortality

Indexed keywords

APOLIPOPROTEIN E; DNA; APOLIPOPROTEIN E4;

AGED; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; COMMUNITY; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL BIOPSY; STROKE; UNITED STATES; AGE DISTRIBUTION; COHORT ANALYSIS; CONFIDENCE INTERVAL; FOLLOW UP; GENE FREQUENCY; GENETICS; LONGITUDINAL STUDY; POPULATION GENETICS; PREVALENCE; RISK FACTOR; SEX RATIO; SURVIVAL;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CARDIOVASCULAR DISEASES; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENETICS, POPULATION; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL ANALYSIS; UTAH;

EID: 23444451472     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2005.53301.x     Document Type: Article

References (50)

1. Eichner JE, Dunn ST, Perveen G et al. Apolipoprotein E polymorphism and cardiovascular disease: A HuGE review. Am J Epidemiol 2002;155:487-495.
2. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1-21.
3. Eichner JE, Kuller LH, Orchard TJ et al. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol 1993;71:160-165.
4. Wilson PWF, Schaefer EJ, Larson MG et al. Apolipoprotein E alleles and risk of coronary disease: A meta-analysis. Arterioscler Thromb Vasc Biol 1996;16:1250-1255.
5. Farrer LA, Cupples LA, Haines JL et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356.
6. Corder EH, Lannfelt L, Viitanen M et al. Apolipoprotein E genotype determines survival in the oldest old (85 years or older) who have good cognition. Arch Neurol 1996;53:418-422.
7. Corder EH, Basun H, Lannfelt L et al. Attenuation of apolipoprotein E epsilon4 allele gene dose in late age. Lancet 1996;347:542.
8. Ewbank DC. Mortality differences by APOE genotype estimated from demographic synthesis. Genet Epidemiol 2002;22:146-155.
9. Skoog I, Hesse C, Aevarsson O et al. A population study of APOE genotype at the age of 85: Relation to dementia, cerebrovascular disease, and mortality. J Neurol Neurosurg Psychiatry 1998;64:37-43.
10. Juva K, Verkkoniemi A, Viramo P et al. APOE epsion4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology 2000;54:412-415.
11. Lee JH, Tang MX, Schupf N et al. Mortality and apolipoprotein E in Hispanic, African-American, and Caucasian elders. Am J Med Genet 2001;103:121-127.
12. Ewbank DC. The APOE gene and differences in life expectancy in Europe. J Gerontol A Biol Sci Med Sci 2004;59A:16-20.
13. Tschanz JT, Corcoran C, Skoog I et al. Dementia: The leading predictor of death in a defined elderly population. The Cache County Study. Neurology 2004;62:1156-1162.
14. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
15. Breitner JC, Wyse BW, Anthony JC et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: The Cache County Study. Neurology 1999;53:321-331.
16. Richards B, Skoletsky J, Shuber AP et al. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet 1993;2:159-163.
17. Saunders AM, Strittmatter WJ, Schmechel D et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
18. Cohen JA. A coefficient of agreement for nominal scales. Educ Psychol Measur 1960;20:34-46.
19. Fleiss JL. Statistical Methods for Rates and Proportions, 2nd Ed. New York: John Wiley and Sons, 1981.
20. Natarajan S, Lipsitz SR, Nietert PJ. Self-report of high cholesterol: Determinants of validity in U. S. adults. Am J Prev Med 2002;23:13-21.
21. Robinson JR, Young TK, Roos LL et al. Estimating the burden of disease. Comparing administrative data and self-reports. Med Care 1997;35:932-947.
22. Vargas CM, Burt VL, Gillum RF et al. Validity of self-reported hypertension in the National Health and Nutrition Examination Survey III, 1988-1991. Prev Med 1997;26(5Part 1):678-685.
23. Tschanz JT, Welsh-Bohmer KA, Plassman BL et al. An adaptation of the modified Mini-Mental State Examination: Analysis of demographic influences and normative data: The Cache County Study. Neuropsychiatry Neuropsychol Behav Neurol 2002;15:28-38.
24. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987;48:314-318.
25. Khachaturian AS, Gallo JJ, Breitner JC. Performance characteristics of a two-stage dementia screen in a population sample. J Clin Epidemiol 2000;53:531-540.
26. Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): Sociodemographic correlates, reliability, validity and some norms. Psychol Med 1989;19:1015-1022.
27. Silverman JM, Breitner JC, Mohs RC et al. Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias. Am J Psychiatry 1986;143:1279-1282.
28. Cummings JL, Mega M, Gray K et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
29. Clark CM, Ewbank DC. Performance of the dementia severity rating scale: A caregiver questionnaire for rating severity in Alzheimer disease. Alzheimer Dis Assoc Disord 1996;10:31-39.
30. Tschanz JT, Welsh-Bohmer KA, Skoog I et al. Dementia diagnoses from clinical and neuropsychological data compared. The Cache County Study. Neurology 2000;54:1290-1296.
31. Diagnostic and Statistical Manual of Mental Disorders, 3rd Ed. Revised. Washington, DC: American Psychiatric Association, 1987.
32. McKhann G, Drachman D, Folstein M et al. Clinical Diagnosis of Alzheimer's Disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
33. Roman GC, Tatemichi TK, Erkinjuntti T et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-260.
34. Tatemichi TK, Paik M, Bagiella E et al. Risk of dementia after stroke in a hospitalized cohort: Results of a longitudinal study. Neurology 1994;44:1885-1891.
35. Hughes CP, Berg L, Danziger WL et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
36. Hayden KM, Khachaturian AS, Tschanz JT et al. Characteristics of a two-stage screen for incident dementia. J Clin Epidemiol 2003;56:1038-1045.
37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
38. Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute, Inc, 1995.
39. Rothman KJ. Epidemiology. An Introduction, 2nd Ed. New York: Oxford University Press, 2002.
40. Levin ML. The occurrence of lung cancer in man. Acta Intern Cancer 1953;9:531.
41. Mahley RW, Rail SC Jr., Apolipoprotein E. Far more than a Lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-537.
42. American Heart Association. Heart Disease and Stroke Statistics-2004 Up-date [on-line]. Dallas, TX. Available at www.americanheart.org. Accessed April 8, 2004.
43. Heijmans BT, Slagboom PE, Gussekloo J et al. Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age. Am J Med Genet 2002;107:201-208.
44. Fillenbaum GG, Burchett BM, Lee JH et al. Mortality and apolipoprotein E in African-American and white elders: An attempted replication. Am J Med Genet 2003;119A:141-146.
45. Louhija J, Viitanen M, Aguero-Torres H et al. Survival in Finnish centenarians in relation to apolipoprotein E polymorphism. J Am Geriatr Soc 2001;49:1007-1008.
46. Dal Forno G, Carson KA, Brookmeyer R et al. APOE genotype and survival in men and women with Alzheimer's disease. Neurology 2002;58:1045-1050.
47. van Duijn CM, de Knijff P, Wehnert A et al. The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Ann Neurol 1995;37:605-610.
48. Eto M, Watanabe K, Makino I. Increased frequencies of apolipoprotein epsilon 2 and epsilon 4 alleles in patients with ischemic heart disease. Clin Genet 1989;36:183-188.
49. Eto M, Watanabe K, Makino I et al. Apolipoprotein E allele frequencies in non-insulin-dependent diabetes mellitus with hypertriglyceridemia (type IIb III, IV, and V hyperlipoproteinemia). Metabolism 1991;40:776-780.
50. Schächter F, Faure-Delanef L, Guenot F et al. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 1994;6:29-32.